Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $54.4 million.

  • Rocket Pharmaceuticals' Total Liabilities fell 1494.59% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.4 million, marking a year-over-year decrease of 1494.59%. This contributed to the annual value of $64.5 million for FY2024, which is 1260.86% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Total Liabilities stood at $54.4 million, which was down 1494.59% from $66.8 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Total Liabilities peaked at $96.5 million during Q1 2021, and registered a low of $42.3 million during Q4 2021.
  • Its 5-year average for Total Liabilities is $58.0 million, with a median of $57.9 million in 2024.
  • Over the last 5 years, Rocket Pharmaceuticals' Total Liabilities had its largest YoY gain of 4687.2% in 2022, and its largest YoY loss of 5592.06% in 2022.
  • Over the past 5 years, Rocket Pharmaceuticals' Total Liabilities (Quarter) stood at $42.3 million in 2021, then soared by 46.87% to $62.1 million in 2022, then rose by 18.75% to $73.8 million in 2023, then decreased by 12.61% to $64.5 million in 2024, then fell by 15.67% to $54.4 million in 2025.
  • Its Total Liabilities was $54.4 million in Q3 2025, compared to $66.8 million in Q2 2025 and $58.9 million in Q1 2025.